Document:

EX-10.30

 Exhibit 10.30 

 
 

 
 CONTRACT PACKING AGREEMENT 

This Contract Packing Agreement (the “Agreement”) is made effective as of November 5, 2018 (the
“Effective Date”) between Me Gusta Gourmet (“Manufacturer”), having its principal offices at 28212 Constellation, Valencia, CA 91355, and The Real Good Food Company LLC, a California Limited Liability Company
(“RGF”) having its principal offices at 111 Maryland Ave, Glendale, CA 91201. Manufacturer and RGF are sometimes hereinafter referred to individually as a “Party” and together as the “Parties”. 

RECITALS: 

A.        Upon the terms and conditions set forth herein, RGF will purchase certain Products (as
defined below) from Manufacturer and will engage Manufacturer to manufacture, package, and ship those Products to the retail sellers listed on Exhibit “1” hereto (hereinafter referred to singularly as a
“Customer” and collectively as the “Customers”). 
 B.        RGF shall be the
vendor of record for each Customer in accordance with each Customer’s vendor/supplier agreement between each Customer and RGF (hereinafter referred to as the “Customer Requirements”).    The Customer Requirements
are attached as Exhibit “2” hereto. 
 C.        The term
“Product” or “Products” as used herein shall mean the products stated in Exhibit “1” hereto. 

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged by the Parties, and in order to induce RGF to
engage Manufacturer for the manufacture of the Products, Manufacturer and RGF agree as follows: 

1.    Recitals. The Parties acknowledge the accuracy of the Recitals and by this reference incorporate them into
this Agreement. 
 2.    Product Specifications and Delivery Requirements. The Product(s) shall be
manufactured, packaged and shipped according to the specifications stated in Exhibit “1” and the Customer Requirements attached as Exhibit “2” hereto, both of which
are incorporated herein by reference as if fully set forth herein. Manufacturer agrees to provide advance written notice to RGF of any change to the manufacturing and production facility used to produce the Products.  

3.    Product Pricing. The Products shall be sold by Manufacturer to RGF at the price(s) stated in
Exhibit “1”, as it may be amended from time to time in accordance with Section 4 hereof. 

4.    Pricing Changes. Any and all proposed changes to the Product pricing after the guarantee as stated in
Exhibit “1” must be submitted in writing to RGF with at least 90 days advance written notice provided any increase will not exceed the actual increase in Manufacturer’s cost of production, as verified by
the supporting documentation reasonably requested by RGF. RGF shall have 30 days from the receipt of a proposed price change to either approve or reject the proposed price change. If a price change is approved, a replacement Exhibit
“1” will be issued and mutually agreed to in a written Addendum signed by RGF and Manufacturer. If Manufacturer increases, or proposes to increase, the price of a Product or Products, RGF may, at its
sole election, elect to terminate this Agreement as to any such Product or Products or portion thereof, provided, however, Manufacturer’s obligations and agreements pursuant to Sections 7, 9, 11, 12, 13, 14, 15, 16, 17, 18, and19 of this
Agreement, and other provisions that by their nature survive termination, shall survive such termination and shall continue indefinitely. 

  

			
	 Page 1 of 9
	  	     / /s/ JO 

 5.    Purchase Order and Delivery Terms. RGF will submit a
purchase order to Manufacturer for all requested Products. Orders are to be manufactured, packaged, and shipped within _________ (___) days _____________ to _____________ and must be received by Customer(s)
within _________ (___) days from the date the purchase order is received. 
 6.    Payment Terms.
Payment from RGF to Manufacturer will be due 30 days after production. 
 7.    Artwork; Packaging; Research
and Development; Manufacturer’s Supply Chain.

(a)        Artwork. RGF shall be responsible for the design of artwork for the
Product packaging and/or labels. The completed artwork shall be submitted electronically to Manufacturer for ordering and production of Product packaging and/or labels. For the purpose of this Agreement, labels shall be considered Packaging as
discussed in 7(b). 
 (b)        Packaging. Packaging supply inventories shall
be ordered and reordered in quantities as defined in Exhibit “1”. All packaging costs, whether fixed or variable, shall be included in the Product Pricing as stated in Exhibit
“1”. During the term of this Agreement, Manufacturer shall conduct a physical inventory of Packaging on the first Monday of each month and submit the totals in writing to RGF. 

(c)        Research and Development. Manufacturer shall create all formulations
necessary for the research and development of the Products and shall pay and be responsible for all costs to develop the Products, including the cost of the ingredients, labor, and shipping necessary to create and distribute samples of the Products.
RGF will pay and be responsible for RGF’s salaries, overhead, and costs (including but not limited to travel costs) necessary to sell and market the Products. 

Notwithstanding Manufacturer’s development of the formulations necessary for research and development of the Products, RGF
shall own all recipes, formulations, trade secrets, confidential or proprietary information and other intellectual property (including but not limited to trademark(s), artwork, artwork design, printer’s artwork distortion files (if applicable),
product packaging, packing mockups, printing proofs, printing plates, drums, and other customary items related to artwork and graphics development) relating to the Products or RGF (collectively, “RGF’s Intellectual Property”); and
Manufacturer shall forward all such information (including but not limited to formulations, formula application, mathematics, ingredient lists, and complete specifications) to RGF (i) prior to first date of shipment, (ii) within ten
(10) days after any specification is changed, (iii) current as of the date of termination of this Agreement within ten (10) days after termination of this Agreement, and (iv) within five (5) days of any request by RGF. 

RGF grants to Manufacturer a revocable, non-exclusive license for the term of this
Agreement to use RGF’s Intellectual Property solely for the purpose of performing Manufacturer’s obligations under this Agreement. Notwithstanding any breach of this Agreement, Manufacturer shall not use RGF’s Intellectual Property
except in accordance with the limited license. Manufacturer acknowledges that by obtaining the limited license to RGF’s Intellectual Property, Manufacturer does not have or acquire any right, title, privilege, interest or license in or to any
of RGF’s Intellectual Property, including without limitation its product formulae and recipes. All of RGF’s Intellectual Property and its Derivatives shall remain the sole and exclusive property of RGF. The term “Derivatives” as
used herein shall mean: (a) for copyrightable or copyrighted material, any translation, abridgment, revision or other form in which an existing work may be recast, transformed or adapted; (b) for patentable or patented material, any
improvement thereon; and (c) for material that is protected by trade secret, any new material derived from such existing trade secret material, including new material which may be protected under copyright, patent and/or trade secret laws.
Manufacturer shall at all times keep RGF’s Intellectual Property and its Derivatives confidential and not divulge the information to any party, except those officers, directors, employees, consultants, agents, advisors, and representatives of
Manufacturer who need to know such information to perform Manufacturer’s obligations under this Agreement. 

  

			
	 Page 2 of 9
	  	     / /s/ JO 

 To the extent that RGF’s Intellectual Property includes property
subject to copyright under which Manufacturer may otherwise claim, Manufacturer agrees that such work is done as a “work for hire” as that term is defined under federal copyright law, and that, as a result, RGF shall own all copyrights in
the work. To the extent that RGF’s Intellectual Property does not qualify as a “work for hire” under applicable law, and to the extent that RGF’s Intellectual Property includes material subject to patent, trademark, trade secret,
or other proprietary right protection, Manufacturer hereby irrevocably and fully transfers and assigns to RGF, its successors and assigns, all right, title, and interest in and to RGF’s Intellectual Property, including but not limited to, all
copyrights, patents, trade secrets, trademarks, and other proprietary rights therein (including renewals thereof). Manufacturer shall execute and deliver such instruments and take such other action as may be required and requested by RGF to carry
out the assignment contemplated by this paragraph. Any documents, magnetically or optically encoded media, or other materials created by Manufacturer pursuant to this Agreement shall be owned by RGF and subject to the terms of this paragraph. 

(d)        Manufacturer’s Supply Chain. Manufacturer shall
keep written record of all ingredients and components used to manufacture the Products to include the country of origin, and the specific region of such country, where each of the ingredients, components or parts of the Products are grown, produced
and/or manufactured. Upon the written request from RGF, Manufacturer shall provide such records to RGF to include applicable production runs or lot codes. Manufacturer agrees that RGF may provide such information to its Customers, or Customer’s
regulators, inspectors or third-party auditors upon request from such Customers. In addition, Manufacturer shall obtain RGF’ written approval prior to making any changes to the Products which includes ingredient or component sources. 

 

	8.	 Agreement Term 

(a)            Term of Agreement. This Agreement will
continue in effect until _5_ years from the Effective Date of this Agreement, subject to any extension of the term of this Agreement pursuant to Section 8(b) or termination in accordance with this Section 8. 

(b)            Extension of Term. Except as otherwise
provided herein, this Agreement shall renew automatically every     5     years on the anniversary of the Effective Date (“Renewal Date”) unless either Party gives written notice of
termination to the other Party any time prior to such Renewal Date. If a Party elects to terminate under this Section 8(b), the effective date of termination shall be the last day of the then current term in which the notice is given.
Termination. 
 i.            In addition to the right of
RGF to terminate this Agreement under Section 8(b), RGF may terminate this Agreement if the Customer stops ordering the Product or terminate this Agreement, in part, as to such flavor(s)/SKU(s) of the Products as the Customer stops order
(“Product Deletion”) by giving written notice of termination or Product Deletion, as the case may be, to Manufacturer and specifying the effective date of termination. The date when such written notice of termination is given by RGF
pursuant to Section 8(b) or this Section 8(c)(i) shall be the “Notice Date.” If RGF terminates this Agreement under Section 8(b) or this Section 8(c)(i), RGF agrees to purchase from Manufacturer, at cost (but not to
exceed the pricing set forth in Exhibit “1”), (a) all raw ingredients proprietary to the Products (or, in the case of Product Deletion, Products that are the subject of Product Deletion) - that is, the
ingredients necessary to manufacture the Products but which are not part of the ingredients needed by Manufacturer to manufacture products for its other customers or such of the Products as are not subject to Product Deletion and which are specified
in a writing delivered by Manufacturer to RGF prior to the first shipment of a Product, (b) Manufacturer’s remaining inventory of finished Products (or, in the case of Product Deletion, Products that are the subject of Product Deletion),
and (c) any Packaging that is exclusively used for Products (or, in the case of Product Deletion, Products that are the subject of Product Deletion) produced under this Agreement; provided, however that such buy back requirement shall not
exceed the lesser of (i) the minimum inventory levels set forth in Exhibit “1” for such proprietary raw ingredients (as defined above), such finished Products, and such Packaging or (ii) the
actual on hand inventory levels on the Notice Date of such proprietary raw ingredients (as defined above), such finished Products, and such Packaging reduced by, in each case, the amount of proprietary raw ingredients needed to fill all orders of
Products ordered after the Notice Date, the number of units of the Products ordered after the Notice Date, and the amount of packaging needed to fill all orders of Products ordered after the Notice Date. 

ii.                RGF may terminate this
Agreement effective immediately and/or cancel an order without liability to Manufacturer (a) if Manufacturer has materially breached this Agreement (subject to the cure provisions for performance issues); or (b) if RGF does not accept the
revised pricing pursuant to Section 4, or (c) on sixty (60) days’ notice with or without cause.

  

			
	 Page 3 of 9
	  	     / /s/ JO 

 9.    Non-Circumvention.
For as long as RGF is selling any of the Products manufactured by Manufacturer directly to Customer(s) and for a period of two years thereafter, Manufacturer will not, directly or indirectly, sell or attempt to sell any of the Products (or any
substantially similar or replacement product, including but not limited to non-major changes in the ingredients of the Products, packaging alterations, changes in quantity or size, and similar changes)
directly to Customer(s), nor shall Manufacturer sell or attempt to sell any of the Products (or any substantially similar or replacement product, including but not limited to non-major changes in the
ingredients of the Products, packaging alterations, changes in quantity or size, and similar changes) to any manufacturer, supplier or other intermediary who then sells such Products to Customer(s). Except as otherwise provided in this Agreement,
including but not limited to Section 4 hereof, while RGF is purchasing Products manufactured by Manufacturer during the term of this Agreement at the price stated in Section 3, and provided there are no unresolved performance issues with
Products Manufacturer’s performance under this Agreement, RGF will not, directly or indirectly, sell or attempt to sell any of the Products (or any substantially similar or replacement product, including but not limited to non-major changes in the ingredients of the Products, packaging alterations, changes in quantity or size, or other like changes) manufactured by another supplier directly to Customer(s). 

10.    Facility Audits and Certifications. Manufacturer shall undergo annual food safety and regulation compliance
audits conducted by an approved third-party firm for all facilities producing the Products. Manufacturer shall fulfill any and all requirements deemed necessary to receive an approved status on the aforementioned audits and shall remain in
compliance with such requirements. Manufacturer shall also maintain (i) any and all certification requirements of Customer(s) and (ii) the requirements as described in Exhibit “2”. Manufacturer
shall submit annual audit reports and current proof of required certifications to RGF electronically. 

11.    Indemnity. 

(a)         Manufacturer Indemnity. Manufacturer shall defend, hold
harmless, and indemnify RGF and its parent company, subsidiaries and affiliates, and their respective directors, officers, employees, contractors, agents, successors and assigns from and against any and all third-party lawsuits, claims, demands,
actions, liabilities, losses, damages, costs and expenses (including attorneys’ fees and court costs) (collectively, “Losses”), for (i) any actual or alleged misappropriation or infringement of any patent, trademark, trade dress,
trade secret, copyright or other right relating to the Products other than claims related to RGF’s Intellectual Property; (ii) bodily injury, including death or sickness to persons, and damage to property resulting from or arising out o
(A) the negligence, acts, or omissions of Manufacturer or its employees, contractors, representatives or agents, or (B) a defect in any Products provided by Manufacturer to RGF under the terms of this Agreement, other than a design defect
in any recipe or formulation provided by RGF; (iii) violation by Manufacturer of any law, statute, ordinance, governmental administrative order, rule, or regulation, including, but not limited to, regulations and requirements of United States
Food and Drug Administration, the laws of the State of California, the California’s Safe Drinking Water and Toxic Enforcement Act of 1986, and other similar laws (collectively, “Law”) relating to the Products or to the components or
ingredients, or violation of Law relating to the manufacture of the Products or any failure by Manufacturer to maintain any required certification(s) or make any required disclosure(s) or warning(s) concerning the Products or the components,
ingredients, or manufacture of the Products; and (iv) any installation by Manufacturer of equipment, fixtures, or other items. In addition, Manufacturer shall assume RGF’s indemnification duties and obligations in favor of Customer(s)
under the Customer Requirements to the extent that Manufacturer’s actions or omissions triggered such indemnification duties and obligations. 

12.    Additional Notice and Reporting Obligations. Whenever Manufacturer acquires information or causes an event
to occur, including shipment of the Products, that would trigger an obligation by RGF to notify, disclose, or report any information to Customer(s) pursuant to the Customer Requirements, Manufacturer shall immediately notify RGF of such
information and/or event and provide to RGF all information necessary for RGF to comply with its obligation(s) to notify, disclose, or report any information to Customer(s) as soon as possible (and, in any event, no later than the number of
days or hours constituting one-half (1/2) the time between such event or acquisition of information and RGF’s deadline to notify, disclose, or report information to Customer(s)). Manufacturer shall
provide such information to RGF in a form capable of being transmitted by RGF to Customer(s) without alteration and in compliance with the Customer Requirements. 

  

			
	 Page 4 of 9
	  	     / /s/ JO 

 Manufacturer shall indemnify RGF against any and all lawsuits, claims,
demands, actions, liabilities, losses, damages, costs and expenses (including attorneys’ fees and court costs), regardless of the cause or alleged cause thereof, and regardless of whether such matters are groundless, fraudulent or false,
arising out of any actual or alleged failure by RGF to notify, disclose, or report any information to Customer(s) pursuant to the Customer Requirements concerning the Products. 

13.    Remedies. Manufacturer’s failure to comply with any of the terms and conditions of this Agreement, the
Customer Requirements, or any order or shipment of the Products shall be grounds for the exercise by RGF of any one or more of the following remedies: 

(a) Cancellation of all or any part of any undelivered order of the Products without notice, including but not limited to the
balance of any remaining installments on a multiple–shipment order of the Products; 
 (b) Rejection (or revocation of
acceptance) of all or any part of any delivered shipment of the Products. Upon rejection or revocation of acceptance of any part of or all of a shipment, RGF may return such shipment or hold it at Manufacturer’s risk and expense. Payment of any
invoice shall not limit RGF’s right to reject or revoke acceptance. RGF’s right to reject and return or hold shipments of the Products at Manufacturer’s expense and risk shall also extend to such Products as may be returned to
Customer(s) by its/their customers. RGF may, at its option, require Manufacturer to grant a full refund or credit to RGF of the price actually paid by any such customer of any Customer for any such item in lieu of replacement with respect to any
item. RGF shall be under no duty to inspect any shipment of the Products, and notice to Manufacturer of rejection shall be deemed given within a reasonable time if given within a reasonable time after notice of defects or deficiencies has been given
to RGF by Customer(s). For any of the Products that is rejected (or acceptance revoked) by Customer(s), RGF may charge to Manufacturer any and all expenses incurred by RGF (including any expenses incurred by any Customer(s) and then charged against
RGF), as evidenced by written documentation, in (i) unpacking, examining, repacking and storing such merchandise (it being agreed that in the absence of proof of a higher expense that the RGF or Customer(s), as applicable, shall claim an
allowance for each rejection at the rate of 10% of the price for each rejection made by RGF or Customer(s)) and (ii) landing and reshipping such merchandise. Unless RGF otherwise agrees in writing, Manufacturer shall not have the right to make
a conforming delivery within the contract time; 
 (c) Termination of all current and future business relationships with
Manufacturer; 
 (d) Assessment of any related monetary fines, fees, or costs actually charged to RGF by any Customer(s);

 (e) Recovery from Manufacturer of any damages sustained by RGF as a result of Manufacturer’s breach or default, as
evidenced by written documentation; and 
 (f) Buyer’s remedies under the Uniform Commercial Code and such other
remedies as are provided under applicable law 
 The Parties further acknowledge that any breach or violation of this
Agreement may be difficult or impossible to calculate in pecuniary damages. Therefore, either Party hereto may avail itself of injunctive relief, specific performance or other equitable relief. 

The remedies stated in this Section 13 are not exclusive and are in addition to all other remedies available to RGF at
law or in equity. 
 14.    Insurance Requirements. During the term of this Agreement and for one (1) year
after any termination, Manufacturer shall obtain and maintain insurance coverage acceptable to RGF in the amounts and with the conditions required by (or exceeding) the Customer Requirements except that RGF and each Customer shall be
named as the Certificate Holders and Insured Parties on all such policies. 
 15.    Forum Selection; Choice of
Law. This Agreement, and any and all disputes arising thereunder relating thereto or that in any way relate to the Products, whether sounding in contract or tort, shall be governed by and construed in accordance with the laws of the State
of California without regard to its laws regarding conflicts of law; and the federal and/or state courts of Los Angeles County, CA, shall have exclusive jurisdiction over any actions or suits relating thereto. RGF and Manufacturer mutually
acknowledge and agree that they shall not raise, and hereby waive, any defenses based upon venue, inconvenience of forum, or lack of personal jurisdiction in any action or suit brought in accordance with the foregoing. Any legal action brought by
Manufacturer against RGF with respect to this Agreement or any in any way relating to the Products shall be filed in one of the above referenced jurisdictions within two (2) years after the cause of action arises or it shall be deemed forever
waived. The Parties acknowledge that they have read and understand this clause and agree willingly to its terms. 
  

  

			
	 Page 5 of 9
	  	     / /s/ JO 

 16.    Termination of RGF’s Supplier/Vendor
Agreement(s) With Customer(s); Survival of Provisions. In the event RGF’s supplier/vendor agreement with any Customer(s) is terminated, RGF shall have no further obligation to Manufacturer concerning the Products as to such
Customer(s); however, Manufacturer’s obligations and agreements pursuant to Sections 7, 9, 11, 12, 13, 14, 15, 16, 17, 18, and19 of this Agreement, and other provisions that by their nature survive termination, shall survive such termination
and shall continue indefinitely. In the event RGF’s supplier/vendor agreement with less than all of the Customers is terminated, this Agreement shall remain in full force and effect as to such other Customer(s). 

17.    No Waiver. No failure or delay by either Party in exercising any right hereunder shall operate as a waiver
thereof, nor shall any single or partial waiver thereof preclude any other or further exercise thereof or the exercise of any other right hereunder. 

18.    Construction/Severability.    Each party acknowledges it has contributed to the drafting
of this Agreement. The language in all parts of this Agreement shall in all cases be construed as a whole according to its fair meaning and not strictly for nor against any Party. The neuter gender includes the masculine and feminine. If any
provision of this Agreement is declared void or unenforceable, such provision shall be deemed severed from this Agreement; and the remaining portions of the Agreement shall remain in full force and effect. The prevailing party of any legal action
brought to enforce or interpret the provisions of this Agreement will be entitled to recover reasonable attorneys’ fees and costs from the non-prevailing party in addition to any other relief which the
prevailing party may be entitled. 
 19.    Authority. Each of the Parties hereto represents and warrants to each
other Party hereto that this Agreement has been duly authorized by all necessary action and that this Agreement constitutes and will constitute a binding obligation of each such Party. 

IN WITNESS WHEREOF, the Parties execute this Agreement, to be effective on the Effective Date. 

 

			
	 ME GUSTA
GOURMET                    
	  	 THE REAL GOOD FOOD COMPANY, LLC

		
	     /s/ Joel
Ortega                                        
        
	  	     /s/ Bryan
Freeman                                       
         

	 By:Joel
Oretga                        
	  	 Bryan Freeman

	 Its:
President                            
	  	 Chief Executive

		
	
            11/06/18         
                           
	  	
            11-7-18          
                                  

	 Date
	  	 Date

  

			
	 Page 6 of 9
	  	     /     

 EXHIBIT 1 

[***] 

  

			
	 Page 7 of 9
	  	     /     

 EXHIBIT 1 – A 

[***] 

  

			
	 Page 8 of 9
	  	     /     

 EXHIBIT 2 

Customer Requirements 

[***] 

  

			
	 Page 9 of 9
	  	     /Exhibit 10.1

  

  

  

  
    Bionano Genomics, Inc.

     

    2020 Inducement Plan

     

    Adopted by the Board of Directors: August 20, 2020

    Amended by the Board of directors: October 6, 2021

    

    

    1.            General.

     

    (a)        Eligible Award Recipients.  The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the
        standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1. A person who previously served as an Employee or Director will not be eligible to receive Awards
        under the Plan, other than following a bona fide period of non-employment. Persons eligible to receive grants of Awards under this Plan are
        referred to in this Plan as “Eligible Employees.” These Awards must be approved by either a majority of the Company’s “Independent Directors” (as such term is defined in Nasdaq Marketplace Rule 5605(a)(2)) or the Company’s compensation committee,
        provided such committee comprises solely Independent Directors (the “Independent Compensation Committee”) in order to comply with
        the exemption from the stockholder approval requirement for “inducement grants” provided under Rule 5635(c)(4) of the Nasdaq Marketplace Rules. Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 (together with any
        analogous rules or guidance effective after the date hereof, the “Inducement Award Rules”).

     

    (b)         Available Awards.  The Plan provides for the grant of the following Awards: (i) Options, (ii) Stock Appreciation Rights, (iii)
        Restricted Stock Awards, (iv) Restricted Stock Unit Awards, (v) Performance Stock Awards, (vi) Performance Cash Awards and (vii) Other Stock Awards.  All Options shall be Nonstatutory Stock Options.

     

    (c)         Purpose.  The Plan, through the grant of Awards, is intended
          to provide (i) an inducement material for certain individuals to enter into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq
          Marketplace Rules, (ii) incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and (iii) a means by which Eligible Employees may be given an opportunity to benefit from increases in value of the
          Common Stock.

     

    2.            Administration.

     

    (a)        Administration by Board.  The Board will administer the Plan; provided, however, that Awards may only be granted by either (i) a majority of the
          Company’s Independent Directors or (ii) the Independent Compensation Committee.
          Subject to those constraints and the other constraints of the Inducement Award Rules, the Board may delegate some of its powers of administration of the Plan to a Committee or Committees, as provided in Section 2(c).

     

    (b)        Powers of Board.  The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan and the Inducement Award
          Rules:

     

    
      1.

      
        

    

    (i)          To
          determine: (A) who will be granted Awards; (B) when and how each Award will be granted; (C) what type of Award will be granted; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise
          or otherwise receive cash or Common Stock under the Award; (E) the number of shares of Common Stock subject to, or the cash value of, an Award; and (F) the Fair Market Value applicable to an Award; provided, however, that Awards may only be
          granted by either (i) a majority of the Company’s Independent Directors or (ii) the Independent Compensation Committee.

     

    (ii)        To
          construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Awards.  The Board, in the exercise of these powers, may correct any defect, omission or
          inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective.

     

    (iii)         To
          settle all controversies regarding the Plan and Awards granted under it.

     

    (iv)        To
          accelerate, in whole or in part, the time at which an Award may be exercised or vest (or the time at which cash or shares of Common Stock may be issued in settlement thereof).

     

    (v)         To suspend or terminate the Plan at any time.  Except as otherwise provided in the Plan or an Award Agreement, suspension or termination of the Plan will not materially impair a Participant’s rights under the Participant’s
        then-outstanding Award without the Participant’s written consent, except as provided in subsection (viii) below.

     

    (vi)       To amend
          the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to certain nonqualified deferred compensation under Section 409A of the Code and/or to ensure the Plan or Awards
          granted under the Plan are exempt from, or compliant with, the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law.  Except as provided in Section 9(a) relating
          to Capitalization Adjustments, if required by applicable law or listing requirements, the Company shall seek stockholder approval for any amendment of the Plan.  Except as otherwise provided in the Plan or an Award Agreement, no amendment of the
          Plan will materially impair a Participant’s rights under an outstanding Award without the Participant’s written consent.

     

    (vii)       To
          submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of Rule 16b-3.

     

    (viii)      To
          approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award
          Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided, however, that a Participant’s rights under any Award will not be impaired by any such amendment unless (A) the Company requests the consent
          of the affected Participant, and (B) such Participant consents in writing. Notwithstanding the foregoing, (1) a Participant’s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines
          that the amendment, taken as a whole, does not materially impair the Participant’s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant’s
          consent (A) to clarify the manner of exemption from, or to bring the Award into compliance with, Section 409A of the Code; or (B) to comply with other applicable laws or listing requirements.

     

    
      2.

      
        

    

    (ix)       Generally,
          to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.

     

    (x)          To
          adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Eligible Employees who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for
          immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).

     

    (c)          Delegation to Committee.

     

    (i)        General.  Subject to the terms of Section 4(b), the Board may delegate some or all of the administration of the Plan to a Committee or Committees.  If
          administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
          delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be construed as being to the Committee or subcommittee, as
          applicable).  Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable).  The Committee may, at any time,
          abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of
          the powers previously delegated.

     

    (ii)         Rule 16b-3 Compliance.  The Committee may consist solely of two or more Non-Employee Directors in accordance with Rule 16b-3.

     

    (d)         Effect of Board’s Decision. All determinations, interpretations and constructions made by the Board in
        good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.

     

    (e)          Repricing; Cancellation and Re-Grant of Awards.  Neither the Board nor any Committee will have the authority to reduce the exercise, purchase or strike
          price of any outstanding Option or SAR, unless the stockholders of the Company have approved such an action within twelve (12) months prior to such an event.

     

    3.            Shares Subject to the Plan.

     

    (a)         Share Reserve.  Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed 3,100,000 shares.  Shares may be issued in connection with a
        merger or acquisition as permitted by Nasdaq Marketplace Rule 5635(c) or, if applicable NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares
        available for issuance under the Plan.

     

    
      3.

      
        

    

    (b)         Reversion of Shares to the Share Reserve. If an Award or any portion thereof (i) expires or otherwise terminates without all of the shares covered by
          such Award having been issued or (ii) is settled in cash (i.e., the Participant receives cash rather than stock), such expiration, termination or
          settlement will not reduce (or otherwise offset) the number of shares of Common Stock that may be available for issuance under the Plan.  If any shares of Common Stock issued pursuant to an Award are forfeited back to or repurchased or reacquired
          by the Company for any reason, including because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased or reacquired will revert to and again become
          available for issuance under the Plan.  Any shares reacquired by the Company in satisfaction of tax withholding obligations on an Award or as consideration for the exercise or purchase price of an Award will again become available for issuance
          under the Plan.

     

    (c)         Source of Shares.  The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased
          by the Company on the open market or otherwise.

     

    4.            Eligibility.

     

    (a)        Eligibility for Specific Awards.  Awards may only be granted to persons who are Eligible Employees described in Section 1(a) of the Plan, where the
          Award is an inducement material to the individual’s entering into employment with the Company or an Affiliate within the meaning of Rule 5635(c)(4) of the Nasdaq Marketplace Rules or is otherwise permitted pursuant to Rule 5635(c) of the Nasdaq
          Marketplace Rules, provided, however, that Awards may not be granted to Eligible Employees who are providing Continuous Service only to any
          “parent” of the Company, as such term is defined in Rule 405 of the Securities Act, unless (i) the stock underlying such Awards is treated as “service recipient stock” under Section 409A of the Code (for example, because the Awards are granted
          pursuant to a corporate transaction such as a spin off transaction), (ii) the Company, in consultation with its legal counsel, has determined that such Awards are otherwise exempt from Section 409A of the Code, or (iii) the Company, in
          consultation with its legal counsel, has determined that such Awards comply with the distribution requirements of Section 409A of the Code.

     

    (b)        Approval Requirements. All Awards must be granted
        either by a majority of the Company’s independent directors or the Independent Compensation Committee.

     

    5.            Provisions relating to Options and Stock Appreciation Rights.

     

    Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be
      Nonstatutory Stock Options at the time of grant. The provisions of separate Options or SARs need not be identical; provided, however, that each Award
      Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions:

     

    
      4.

      
        

    

    (a)          Term.  No Option or SAR will be exercisable after the expiration of 10 years from the date of its grant or such shorter period specified in the Award
          Agreement.

     

    (b)          Exercise Price.  The exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to
          the Option or SAR on the date the Award is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Award if such Award is
          granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A of the Code.  Each SAR will be denominated in
          shares of Common Stock equivalents.

     

    (c)          Purchase Price for Options.  The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the
        extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below.  The Board will have the authority to grant Options that do not permit all of the following
        methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment.  The permitted methods of payment are as follows:

     

    (i)           by
          cash, check, bank draft or money order payable to the Company;

     

    (ii)         pursuant
          to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable
          instructions to pay the aggregate exercise price to the Company from the sales proceeds;

     

    (iii)        by
          delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;

     

    (iv)       by a “net
          exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; provided, however, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate
          exercise price not satisfied by such reduction in the number of whole shares to be issued.  Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise
          are used to pay the exercise price pursuant to the “net exercise,” (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations;  or

     

    (v)          in any
          other form of legal consideration that may be acceptable to the Board and specified in the applicable Award Agreement.

     

    
      5.

      
        

    

    (d)        Exercise and Payment of a SAR.  To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance
          with the provisions of the Stock Appreciation Right Agreement evidencing such SAR.  The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on
          the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such
          date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date.  The
          appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR.

     

    (e)         Transferability of Options and SARs.  The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the
          Board will determine.  In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs will apply:

     

    (i)          Restrictions on Transfer.  An Option or SAR will not be transferable except by will or by the laws of descent and distribution (or pursuant to
          subsections (ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant.  The Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities
          laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration.

     

    (ii)       Domestic Relations Orders.  Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the
          terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument.

     

    (iii)       Beneficiary Designation.  Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the
          Company, in a form approved by the Company (or the designated broker), designate a third party who, on the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration
          resulting from such exercise.  In the absence of such a designation, upon the death of the Participant the executor or administrator of the Participant’s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other
          consideration resulting from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable
          laws.

     

    (f)        Vesting Generally.  The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic
        installments that may or may not be equal.  The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria)
        as the Board may deem appropriate.  The vesting provisions of individual Options or SARs may vary.  The provisions of this Section(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an
        Option or SAR may be exercised.

     

    
      6.

      
        

    

    (g)         Termination of Continuous Service.  Except as otherwise provided in the
            applicable Award Agreement or other agreement between the Participant and the Company, if a Participant’s Continuous Service terminates (other than for Cause and other than upon the Participant’s death or Disability), the Participant may
            exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Award as of the date of termination of Continuous Service) within the period of time ending on the earlier of (i) the date that is three
          (3) months following the termination of the Participant’s Continuous Service (or such longer
            or shorter period specified in the applicable Award Agreement, which period will not be less than thirty (30) days if necessary to comply with applicable laws unless such termination is for Cause) and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement.  If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR
            (as applicable) within the applicable time frame, the Option or SAR will terminate.

     

    (h)         Extension of Termination Date.  Except as otherwise provided in the applicable Award Agreement or other written agreement between the
        Participant and the Company, if the exercise of an Option or SAR following the termination of the Participant’s Continuous Service (other than for Cause and other than upon the Participant’s death or Disability) would be prohibited at any time
        solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be
        consecutive) equal to the applicable post-termination exercise period after the termination of the Participant’s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, and (ii)
        the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.  In addition, unless otherwise provided in a Participant’s Award Agreement, if the sale of any Common
        Stock received on exercise of an Option or SAR following the termination of the Participant’s Continuous Service (other than for Cause) would violate the Company’s insider trading policy, then the Option or SAR will terminate on the earlier of (i)
        the expiration of a period of months (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant’s Continuous Service during which the sale of the Common Stock received upon
        exercise of the Option or SAR would not be in violation of the Company’s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.

     

    (i)          Disability of Participant.  Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant
        and the Company, if a Participant’s Continuous Service terminates as a result of the Participant’s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as
        of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date twelve (12) months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement, which period will not be less than six (6) months if necessary to comply with applicable laws) and (ii) the expiration of the
        term of the Option or SAR as set forth in the Award Agreement.  If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option or SAR (as applicable) will
        terminate.

     

    
      7.

      
        

    

    (j)          Death of Participant.  Except as otherwise provided in the applicable Award Agreement or other agreement between the
          Participant and the Company, if (i) a Participant’s Continuous Service terminates as a result of the Participant’s death, or (ii) the Participant dies within the period (if any) specified in the Award Agreement for exercisability after the
          termination of the Participant’s Continuous Service for a reason other than death, then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant’s
          estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant’s death, but only within the period ending on the earlier of (i) the
          date eighteen (18) months following the date of death (or such longer or shorter period specified in the Award Agreement, which period will not be
            less than six (6) months if necessary to comply with the applicable laws) and (ii) the expiration of the term of such Option or SAR as set forth in the Award Agreement.  If, after the Participant’s death, the Option or SAR is not
          exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.

     

    (k)        Termination for Cause.  Except as explicitly provided otherwise in a Participant’s Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant’s Continuous Service is terminated for Cause, the Option or SAR will
          terminate immediately upon such Participant’s termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service.

     

    (l)          Non-Exempt Employees.  If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938,
          as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six (6) months following the date of grant of the Option or SAR (although the Award may vest prior to such date). Consistent with the
          provisions of the Worker Economic Opportunity Act, (i) if such non-exempt Employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in
          Control, or (iv) upon the Participant’s retirement (as such term may be defined in the Participant’s Award Agreement, in another agreement between the Participant and the Company, or, if no such definition, in accordance with the Company’s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six (6) months following the date of grant. 
          The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or
          required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Award will be exempt from the
          employee’s regular rate of pay, the provisions of this Section 5(l) will apply to all Awards and are hereby incorporated by reference into such Award Agreements.

     

    6.            Provisions of Awards Other than Options and SARs.

     

    (a)         Restricted Stock Awards.  Each Restricted Stock Award Agreement will be in such form and will contain such
        terms and conditions as the Board deems appropriate.  To the extent consistent with the Company’s bylaws, at the Board’s election, shares of Common Stock may be (i)
        held in book entry form subject to the Company’s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the
        Board.  The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical.  Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following
        provisions:

     

    
      8.

      
        

    

    (i)        Consideration.  A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B)
          past or future services to the Company or an Affiliate, or (C) any other form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.

     

    (ii)        Vesting.  Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a
          vesting schedule to be determined by the Board.

     

    (iii)        Termination of Participant’s Continuous Service.  If a Participant’s Continuous Service terminates, the Company may receive through a forfeiture
          condition or a repurchase right any or all of the shares of Common Stock held by the Participant as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.

     

    (iv)        Transferability.  Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon
          such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the
          Restricted Stock Award Agreement.

     

    (v)          Dividends.  A Restricted Stock Award Agreement may provide that any dividends paid on Restricted Stock will be subject to the same vesting and
          forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate.

     

    (b)        Restricted Stock Unit Awards.  Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and
        conditions as the Board deems appropriate.  The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical. 
        Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:

     

    (i)          Consideration.  At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid
        by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award.  The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid
        in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.

     

    (ii)         Vesting.  At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.

     

    (iii)        Payment.  A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any
        combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.

     

    
      9.

      
        

    

    (iv)       Additional Restrictions.  At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions
          or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.

     

    (v)        Dividend Equivalents.  Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as
          determined by the Board and contained in the Restricted Stock Unit Award Agreement.  At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award
          in such manner as determined by the Board.  Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Restricted
          Stock Unit Award Agreement to which they relate.

     

    (vi)        Termination of Participant’s Continuous Service.  Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement or other written agreement between a Participant and the Company or an Affiliate, such portion of the Restricted Stock Unit Award that has not
          vested will be forfeited upon the Participant’s termination of Continuous Service.

     

    (c)          Performance Awards.

     

    (i)          Performance Stock Awards.  A Performance Stock Award is an Award that is payable
        (including that may be granted, may vest or may be exercised) contingent upon the attainment during a Performance Period of certain Performance Goals.  A Performance Stock Award may, but need not, require the Participant’s completion of a specified
        period of Continuous Service. The length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively
        determined by the Board or Committee, in its sole discretion.  In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board or the Committee may determine that cash may be used in payment of Performance Stock
        Awards.

     

    (ii)         Performance Cash Awards.  A Performance Cash Award is a cash award that is payable contingent upon the attainment during a Performance Period of
          certain Performance Goals.  A Performance Cash Award may also require the completion of a specified period of Continuous Service.  At the time of grant of a Performance Cash Award, the length of any Performance Period, the Performance Goals to be
          achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Board or Committee, in its sole discretion.  The Board or Committee may specify
          the form of payment of Performance Cash Awards, which may be cash or other property, or may provide for a Participant to have the option for his or her Performance Cash Award, or such portion thereof as the Board may specify, to be paid in whole
          or in part in cash or other property.

     

    
      10.

      
        

    

    (iii)      Discretion.  A majority of the Company’s Independent Directors or the Independent Compensation Committee retains the discretion to adjust or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to
          define the manner of calculating the Performance Criteria it selects to use for a Performance Period.  Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in
          the Award Agreement or the written terms of a Performance Cash Award.

     

    (d)         Other Stock Awards.  Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock,
        including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Awards
        provided for under Section 5 and the preceding provisions of this Section 6.  Subject to the provisions of the Plan, a majority of the Company’s Independent Directors or the Independent Compensation Committee will have sole and complete authority
        to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and
        conditions of such Other Stock Awards.

     

    7.            Covenants of the Company.

     

    (a)         Availability of Shares.  The Company will keep available at all times the number of shares of Common Stock reasonably required to
        satisfy then-outstanding Awards.

     

    (b)         Securities Law Compliance.  The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan, as necessary,
          such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Awards; provided, however,
          that this undertaking will not require the Company to register under the Securities Act, or other securities or applicable laws, the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award.  If, after reasonable efforts
          and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the
          Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise or vesting of such Awards unless and until such authority is obtained. A Participant will not be eligible for the grant of an Award or the
          subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in violation of any applicable securities law.

     

    (c)          No Obligation to Notify or Minimize Taxes.  The Company will have no duty or obligation to any Participant to advise such holder as to the tax
          treatment or time or manner of exercising such Award.  Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may
          not be exercised.  The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award.

     

    
      11.

      
        

    

    8.            Miscellaneous.

     

    (a)         Use of Proceeds from Sales of Common Stock.  Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the
          Company.

     

    (b)          Corporate Action Constituting Grant of Awards.  Corporate action constituting a grant by the Company of an Award to any Participant will be deemed
          completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. 
          In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with
          those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right
          to the incorrect term in the Award Agreement or related grant documents.

     

    (c)          Stockholder Rights.  No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common
          Stock subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to
          such Award has been entered into the books and records of the Company.

     

    (d)          No Employment or Other Service Rights. Nothing in the Plan, any Award
            Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the
          time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such
          Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state or foreign jurisdiction in which
          the Company or the Affiliate is domiciled or incorporated, as the case may be.

     

    (e)          Change in Time Commitment.  In the event a Participant’s regular level of time commitment in the performance of his or her services for the Company and
          any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence)
          after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or
          become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will
          have no right with respect to any portion of the Award that is so reduced or extended.

     

    
      12.

      
        

    

    (f)         Investment Assurances.  The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award, (i) to give
          written assurances satisfactory to the Company as to the Participant’s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and
          experienced in financial and business matters and that such Participant is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Award; and (ii) to give written assurances satisfactory
          to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant’s own account and not with any present intention of selling or otherwise distributing the Common Stock.  The foregoing requirements,
          and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock under the Award has been registered under a then currently effective registration
          statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws.  The Company
          may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends
          restricting the transfer of the Common Stock.

     

    (g)         Withholding Obligations.  Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any
        federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii)  withholding shares of Common Stock from the shares
        of Common Stock issued or otherwise issuable to the Participant in connection with the Award; provided, however, that no shares of Common Stock are
        withheld with a value exceeding the maximum amount of tax required to be withheld by law (or such lesser amount as may be necessary to avoid classification of the Award as a liability for financial accounting purposes); (iii) withholding cash from
        an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Award Agreement.

     

    (h)        Electronic Delivery.  Any reference herein to a “written” agreement or document will include any agreement or document delivered electronically, filed
          publicly at www.sec.gov (or any successor website thereto) or posted on the Company’s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).

     

    (i)          Deferrals.  To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the
          payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants.  Deferrals by Participants will be made in
          accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company.  The Board is authorized to make
          deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant’s termination of Continuous Service, and implement such other terms and conditions
          consistent with the provisions of the Plan and in accordance with applicable law.

     

    
      13.

      
        

    

    (j)        Compliance with Section 409A of the Code.  Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be
          interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code.  If the Board
          determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified
          in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement.  Notwithstanding anything to the contrary in this Plan
          (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes “deferred compensation” under Section 409A of the Code is a “specified
          employee” for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a “separation from service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) will be
          issued or paid before the date that is six months following the date of such Participant’s “separation from service” (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the
          Participant’s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance
          paid thereafter on the original schedule.

     

    (k)         Clawback/Recovery.  All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the
        Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection
        Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in
        respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of an event constituting Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a right to voluntary
        terminate employment upon “resignation” for “good reason” or for a “constructive termination” or any similar term under any plan of or agreement with the Company.

     

    9.            Adjustments upon Changes in Common Stock; Other Corporate Events.

     

    (a)          Capitalization Adjustments.  In the event of a Capitalization Adjustment, the Board will appropriately and
        proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a); and (ii) the class(es) and number of securities and price per share of stock subject to outstanding Awards.  The Board will
        make such adjustments, and its determination will be final, binding and conclusive.

     

    
      14.

      
        

    

    (b)         Dissolution.  Except as otherwise provided in the Award Agreement, in the event of a Dissolution of the Company, all outstanding Awards (other than
          Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company’s right of repurchase) will terminate immediately prior to the completion of such Dissolution, and the shares of Common Stock
          subject to the Company’s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service; provided, however, that the Board may, in its sole discretion, cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or
          forfeiture (to the extent such Awards have not previously expired or terminated) before the Dissolution is completed but contingent on its completion.

     

    (c)         Transaction.  The following provisions will apply to Awards in the event of a Transaction unless otherwise provided in the instrument evidencing the
          Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of an Award.  In the event of a Transaction, then, notwithstanding any other
          provision of the Plan, the Board may take one or more of the following actions with respect to Awards, contingent upon the closing or completion of the Transaction:

     

    (i)         arrange
          for the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company) to assume or continue the Award or to substitute a similar stock award for the Award (including, but not limited to, an award to
          acquire the same consideration paid to the stockholders of the Company pursuant to the Transaction);

     

    (ii)        arrange
          for the assignment of any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to the Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent
          company);

     

    (iii)        accelerate the vesting, in whole or in part, of the Award (and, if applicable, the time at which the Award may be exercised) to a date prior to the effective time of such Transaction as the Board determines (or, if the Board does not
        determine such a date, to the date that is five days prior to the effective date of the Transaction), with such Award terminating if not exercised (if applicable) at or prior to the effective time of the Transaction; provided, however, that the
        Board may require Participants to complete and deliver to the Company a notice of exercise before the effective date of a Transaction, which exercise is contingent upon the effectiveness of such Transaction;

     

    (iv)       arrange
          for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the Award;

     

    (v)        cancel or
          arrange for the cancellation of the Award, to the extent not vested or not exercised prior to the effective time of the Transaction, in exchange for such cash consideration, if any, as the Board, in its sole discretion, may consider appropriate;
          and

     

    (vi)        make a
          payment, in such form as may be determined by the Board equal to the excess, if any, of (A) the value of the property the Participant would have received upon the exercise of the Award immediately prior to the effective time of the Transaction,
          over (B) any exercise price payable by such holder in connection with such exercise.  For clarity, this payment may be $0 if the value of the property is equal to or less
            than the exercise price.  Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company’s Common Stock in connection with the Transaction is delayed as a result of escrows, earn
            outs, holdbacks or other contingencies.

     

    
      15.

      
        

    

    The Board need not take the same action or actions with respect to all Awards or portions thereof or with respect to all Participants. The Board may take different actions with respect to the vested and unvested portions of an Award.

     

    (d)         Change in Control.  An Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control as may be
          provided in the Award Agreement for such Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration will automatically occur.

     

    10.          Termination or Suspension of the Plan.

     

    The Board may suspend or terminate the Plan at any time. No Awards may be granted under the Plan while the Plan is suspended or after it is
      terminated.

     

    11.          Effective Date of the Plan.

     

    The Plan will come into existence on the Effective Date.

     

    12.          Choice of Law.

     

    The laws of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without
      regard to that state’s conflict of laws rules.

     

    13.          Definitions.  As used in the Plan, the following definitions will apply to the capitalized terms indicated below:

     

    (a)          “Affiliate” means, at the time of determination, any “parent” or “subsidiary” of the Company as such terms are defined in Rule 405
          of the Securities Act.  The Board will have the authority to determine the time or times at which “parent” or “subsidiary” status is determined within the foregoing definition.

     

    (b)         “Award” means an Option, a Stock Appreciation Right, a
            Restricted Stock Award, a Restricted Stock Unit Award, a Performance Stock Award, a Performance Cash Award or an Other Stock Award.

     

    (c)          “Award Agreement” means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.

     

    (d)          “Board” means the Board of Directors of the Company.

     

    (e)          “Capitalization Adjustment” means any change that is made in, or other events that occur with respect to, the Common Stock subject
          to the Plan or subject to any Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than
          cash, large nonrecurring cash dividend, stock split, reverse stock split liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in
          Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).  Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a
          Capitalization Adjustment.

     

    
      16.

      
        

    

    (f)          “Cause” shall
          have the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the
          following events:  (i) such Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) such Participant’s attempted commission of, or
          participation in, a fraud or act of dishonesty against the Company; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant and the Company or of any statutory duty owed to the Company;
          (iv) such Participant’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or (v) such Participant’s gross misconduct. The determination that a termination of the Participant’s Continuous Service is either
          for Cause or without Cause shall be made by the Company, in its sole discretion.  Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by
          such Participant shall have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose.

     

    (g)        “Change in Control” means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the
          following events:

     

    (i)          any
          Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or
          similar transaction.  Notwithstanding the foregoing, a Change in Control will not be deemed to occur (A) on account of the acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the
          Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through
          the issuance of equity securities, (C) on account of the acquisition of securities of the Company by any individual who is, on the IPO Date, either an executive officer or a Director (either, an “IPO Investor”) and/or any entity in which an IPO Investor has a direct or indirect interest (whether in the form of voting rights or participation in profits or capital
          contributions) of more than 50% (collectively, the “IPO Entities”) or on account of the IPO Entities continuing to hold shares
          that come to represent more than 50% of the combined voting power of the Company’s then outstanding securities as a result of the conversion of any class of the Company’s securities into another class of the Company’s securities having a
          different number of votes per share pursuant to the conversion provisions set forth in the Company’s Amended and Restated Certificate of Incorporation; or (D) solely because the level of Ownership held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or
          other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the
          Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting
          securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control will be deemed to occur;

     

    
      17.

      
        

    

    (ii)      there is
          consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately
          prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B)
          more than 50% of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting
          securities of the Company immediately prior to such transaction; provided, however, that a merger, consolidation or similar transaction will not
          constitute a Change in Control under this prong of the definition if the outstanding voting securities representing more than 50% of the combined voting power of the surviving Entity or its parent are owned by the IPO Entities;

     

    (iii)        there
          is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of
          the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their
          Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; provided, however,
          that a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries will not constitute a Change in Control under this prong of the definition if the outstanding
          voting securities representing more than 50% of the combined voting power of the acquiring Entity or its parent are owned by the IPO Entities;

     

    (iv)         the
          stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company will otherwise occur, except for a liquidation into a parent
          corporation; or

     

    (v)          individuals
          who, on the IPO Date, are members of the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority
          of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was
          approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member will, for purposes of this Plan, be considered as a member of the Incumbent Board.

     

    Notwithstanding the foregoing definition or any other provision of the Plan, (A) the term Change in Control will not include a sale of
      assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company and (B) the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any
      Affiliate and the Participant will supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no
      definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition will apply.

     

    
      18.

      
        

    

    (h)          “Code” means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.

     

    (i)          “Committee” means a committee of one or more Independent Directors to whom authority has been delegated by the Board in accordance
          with Section 2(c).

     

    (j)          “Common Stock” means the common stock of the Company having one vote per share.

     

    (k)          “Company” means Bionano Genomics, Inc., a Delaware corporation.

     

    (l)          “Consultant” means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a
          member of the board of directors of an Affiliate and is compensated for such services.  However, service solely as a Director, or payment of a fee for such service, will not
            cause a Director to be considered a “Consultant” for purposes of the Plan. Notwithstanding the foregoing, a person is
          treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the
            Company’s securities to such person.

     

    (m)      “Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Director or
          Consultant, is not interrupted or terminated.  A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders
          such service, provided that there is no interruption or termination of the Participant’s service with the Company or an Affiliate, will not terminate a Participant’s Continuous Service; provided, however, that if the Entity for which a Participant is rendering services ceases to qualify
          as an Affiliate, as determined by the Board, in its sole discretion, such Participant’s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate.  To the extent permitted by law, the Board
          or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer,
          including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors.  Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of
          vesting in an Award only to such extent as may be provided in the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law.

     

    (n)          “Corporate Transaction” means the consummation, in a single transaction or in a series of related transactions, of any one or more
          of the following events:

     

    (i)          a sale or other disposition of all or substantially all, as determined by the Board, in its sole discretion, of the consolidated assets of the Company and
          its Subsidiaries;

     

    (ii)          a sale
          or other disposition of more than 50% of the outstanding securities of the Company;

     

    
      19.

      
        

    

    (iii)        a
          merger, consolidation or similar transaction following which the Company is not the surviving corporation; or

     

    (iv)      a merger,
          consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue
          of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.

     

    (o)          “Director” means a member of the Board.  Directors are not eligible to receive Awards under the Plan with respect to their service
          in such capacity.

     

    (p)          “Disability” means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity
          by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and
          409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.

     

    (q)          “Dissolution” means when the Company, after having executed a certificate of dissolution with the State of Delaware (or other
          applicable state), has completely wound up its affairs.  Conversion of the Company into a Limited Liability Company (or any other pass-through entity) will not be considered a “Dissolution” for purposes of the Plan.

     

    (r)          “Effective Date” means August 20, 2020.

     

    (s)          “Employee” means any person employed by the Company or an Affiliate.  However, service solely as a Director, or payment of a fee for
          such services, will not cause a Director to be considered an “Employee” for purposes of the Plan.

     

    (t)          “Entity” means a corporation, partnership, limited liability company or other entity.

     

    (u)          “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

     

    (v)          “Exchange Act Person” means
          any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the
          Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to a
          registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or
          “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the IPO Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company’s then
          outstanding securities.

     

    
      20.

      
        

    

    (w)         “Fair Market Value” means, as of any date, the value of the Common Stock determined as follows:

     

    (i)          If the
          Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on
          such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.

     

    (ii)        Unless
          otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.

     

    (iii)        In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Section 409A of the Code.

     

    (x)       “IPO Date” means the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public
          offering of securities of the Company, pursuant to which such securities are priced for the initial public offering.

     

    (y)         “Non-Employee Director” means a
          Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity
          other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (“Regulation S-K”)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship
          for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is otherwise considered a “non-employee director” for purposes of Rule 16b-3.

     

    (z)        “Nonstatutory Stock Option” means any option granted pursuant to Section 5 of the Plan that does not qualify as an “incentive stock
          option” within the meaning of Section 422 of the Code.

     

    (aa)        “Officer” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.

     

    (bb)       “Option” means a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.

     

    (cc)       “Option Agreement” means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an
          Option grant.  Each Option Agreement will be subject to the terms and conditions of the Plan.

     

    (dd)      “Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an
          outstanding Option.

     

    
      21.

      
        

    

    (ee)        “Other Stock Award” means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms
          and conditions of Section 6(d).

     

    (ff)         “Other Stock Award Agreement” means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant.  Each Other Stock Award Agreement will be subject to the
        terms and conditions of the Plan.

     

    (gg)        “Own,” “Owned,” “Owner,” “Ownership” means a person or
          Entity will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise,
          has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.

     

    (hh)     “Participant” means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an
          outstanding Award.

     

    (ii)          “Performance Cash Award” means an award of cash granted pursuant to the terms and conditions of Section 6(c)(ii).

     

    (jj)       “Performance Criteria” means the one or more criteria that a majority of the Company’s Independent Directors or the Independent Compensation Committee will select for
          purposes of establishing the Performance Goals for a Performance Period.  The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by a majority of
          the Company’s Independent Directors or the Independent Compensation Committee: (i)
          sales; (ii) revenues; (iii) assets; (iv) expenses; (v) market penetration or expansion; (vi) earnings from operations; (vii) earnings before or after deduction for all or any portion of interest, taxes, depreciation, amortization, incentives,
          service fees or extraordinary or special items, whether or not on a continuing operations or an aggregate or per share basis; (viii) net income or net income per common share (basic or diluted); (ix) return on equity, investment, capital or
          assets; (x) one or more operating ratios; (xi) borrowing levels, leverage ratios or credit rating; (xii) market share; (xiii) capital expenditures; (xiv) cash flow, free cash flow, cash flow return on investment, or net cash provided by
          operations; (xv) stock price, dividends or total stockholder return; (xvi) development of new technologies or products; (xvii) sales of particular products or services; (xviii) economic value created or added; (xix) operating margin or profit
          margin; (xx) customer acquisition or retention; (xxi) raising or refinancing of capital; (xxii) successful hiring of key individuals; (xxiii) resolution of significant litigation; (xxiv) acquisitions and divestitures (in whole or in part); (xxv)
          joint ventures and strategic alliances; (xxvi) spin-offs, split-ups and the like; (xxvii) reorganizations; (xxviii) recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings; (xxix) or strategic business criteria,
          consisting of one or more objectives based on the following goals: achievement of timely development, design management or enrollment, meeting specified market penetration or value added, payor acceptance, patient adherence, peer reviewed
          publications, issuance of new patents, establishment of or securing of licenses to intellectual property, product development or introduction (including, without limitation, discovery of novel products, maintenance of multiple products in
          pipeline, product launch or other product development milestones), geographic business expansion, cost targets, cost reductions or savings, customer satisfaction, operating efficiency, acquisition or retention, employee satisfaction, information
          technology, corporate development (including, without limitation, licenses, innovation, research or establishment of third party collaborations), manufacturing or process development, legal compliance or risk reduction, patent application or
          issuance goals, or goals relating to acquisitions, divestitures or other business combinations (in whole or in part), joint ventures or strategic alliances; and (xxx) other measures of performance selected by the Company’s Independent Directors or the Independent Compensation Committee.

     

    
      22.

      
        

    

    (kk)       “Performance Goals” means, for a Performance Period, the one or more goals established by a majority of the Company’s Independent Directors or the Independent Compensation Committee for the Performance
          Period based upon the Performance Criteria.  Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the
          performance of one or more comparable companies or the performance of one or more relevant indices.  The Company’s Independent Directors or the Independent Compensation Committee are authorized at any time in its sole discretion, to adjust or modify the calculation of a Performance Goal for such Performance
          Period in order to prevent the dilution or enlargement of the rights of Participants, (a) in the event of, or in anticipation of, any unusual or extraordinary corporate item, transaction, event or development; (b) in recognition of, or in
          anticipation of, any other unusual or nonrecurring events affecting the Company, or the financial statements of the Company in response to, or in anticipation of, changes in applicable laws, regulations, accounting principles, or business
          conditions; or (c) in view of the Company’s Independent Directors or the Independent
            Compensation Committee’s assessment of the business strategy of the Company, performance of comparable organizations, economic and business conditions, and any other circumstances deemed relevant. Specifically, the Company’s Independent Directors or the Independent Compensation Committee are authorized to make
          adjustment in the method of calculating attainment of Performance Goals and objectives for a Performance Period as follows: (i) to exclude the dilutive effects of acquisitions or joint ventures; (ii) to assume that any business divested by the
          Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; and (iii) to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of
          any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular
          cash dividends. In addition, the Company’s Independent Directors or the Independent
            Compensation Committee are authorized to make adjustment in the method of calculating attainment of Performance Goals and objectives for a Performance Period as follows: (i) to exclude restructuring and/or other nonrecurring charges;
          (ii) to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated net sales and operating earnings; (iii) to exclude the effects of changes to generally accepted accounting standards required by the Financial Accounting
          Standards Board; (iv) to exclude the effects of any items that are “unusual” in nature or occur “infrequently” as determined under generally accepted accounting principles; (v) to exclude the effects to any statutory adjustments to corporate tax
          rates; and (vi) to make other appropriate adjustments selected by the Company’s Independent Directors or the Independent Compensation Committee.

     

    (ll)       “Performance Period” means the period of time selected by a majority of the Company’s Independent Directors or the Independent Compensation Committee over which the attainment of one or more Performance Goals
          will be measured for the purpose of determining a Participant’s right to and the payment of an Award.  Performance Periods may be of varying and overlapping duration, at the sole discretion of a majority of the Company’s Independent Directors or the Independent Compensation Committee.

     

    
      23.

      
        

    

    (mm)     “Performance Stock Award” means an Award granted under the terms and conditions of Section 6(c)(i).

     

    (nn)       “Plan” means this Bionano Genomics, Inc. 2020 Inducement Plan, as it may be amended.

     

    (oo)       “Restricted Stock Award” means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section
          6(a).

     

    (pp)     “Restricted Stock Award Agreement” means a written agreement between the Company and a holder of a Restricted Stock Award evidencing
          the terms and conditions of a Restricted Stock Award grant.  Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.

     

    (qq)       “Restricted Stock Unit Award” means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b).

     

    (rr)       “Restricted Stock Unit Award Agreement” means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant.  Each Restricted Stock Unit
        Award Agreement will be subject to the terms and conditions of the Plan.

     

    (ss)         “Rule 16b-3” means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.

     

    (tt)         “Securities Act” means the Securities Act of 1933, as amended.

     

    (uu)       “Stock Appreciation Right” or “SAR” means a right to receive the appreciation on Common Stock that is granted pursuant to the
          terms and conditions of Section 5.

     

    (vv)       “Stock Appreciation Right Agreement” means a written agreement between the Company and a holder of a Stock Appreciation Right
          evidencing the terms and conditions of a Stock Appreciation Right grant.  Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.

     

    (ww)      “Subsidiary” means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having
          ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening
          of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or
          participation in profits or capital contribution) of more than 50%.

     

    (xx)        “Transaction” means a Corporate Transaction or a Change in Control.

     

     

    

    
      24.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]